RNA interference mediated inhibition of muscarinic...

Details RNA interference mediated inhibition of muscarinic... RNA interference mediated inhibition of muscarinic...

2010-11-19

2011-12-13

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A

Reexamination Certificate

active

08076472

ABSTRACT:
The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3).

REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6346398 (2002-02-01), Pavco et al.
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/14090 (1990-11-01), None
patent: WO-94/01550 (1994-01-01), None
patent: WO-99/13886 (1999-03-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/49029 (1999-09-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/44914 (2000-08-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-02/22636 (2002-03-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/096927 (2002-12-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Bertrand et al. “Comparison of Antisense Oligonucleotides and siRNAs in Cell Culture and In Vivo,” Biochem. Biophys. Res. Comm. 296:1000-1004 (2002).
Braasch et al. “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochem. 41(14):4503-4510 (2002).
Caplen “RNAi as a gene therapy approach,” Expert Opin. Biol. Ther. 3(4):575-586 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Forsythe et al. “Structure and Transcription of the Human m3Muscarinic Receptor Gene,” Am. J. Respir. Cell Mol. Biol. 26:298-305 (2002).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
Hammond et al. “Post-Transcriptional Gene Silencing by Double-Stranded RNA,” Nature 2:110-119 (2001).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Kurreck et al. “Design of Antisense Oligonucleotides Stabiliized by Locked Nucleic Acids,” Nucl. Acids Res. 30:1911-1918 (2002).
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Olie et al. “Analysis of Ribosyl-Modified, Mixed Backbone Analogs of a bcl-2/bcl-xL Antisnesne Oligonucleotide,” Biochim. Biophys.Acta 1576:101-109 (2002).
Parrish et al. “Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference,” Mol. Cell 6:1077-1087 (2002).
Sato et al. “Diversity of mRNA Expression for Muscarinic Acetycholine Receptor Subtypes and Neuronal Nicotinic Acetycholine Receptor Subunits in Human Mononuclear Leukocytes and Leukemic Cell Lines,” Neuroscience Letters 286:17-20 (1999).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Zhang et al. “Single Processing Center Models for Human Dicer and Bacterial RNase III,:” Cell 118:57-68 (2004).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Aug. 8, 2005 for U.S. Appl. No. 10/798,090, 14 pages.
Office Action mailed on Dec. 13, 2005 for U.S. Appl. No. 10/798,090, 11 pages.
Office Action mailed on Jul. 24, 2006 for U.S. Appl. No. 10/798,090, 18 pages.
Office Action mailed on Apr. 18, 2007 for U.S. Appl. No. 10/798,090, 8 pages.
Office Action mailed on Dec. 18, 2007 for U.S. Appl. No. 10/798,090, 38 pages.
Office Action mailed on Jul. 31, 2008 for U.S. Appl. No. 10/798,090, 20 pages.
Office Action mailed on Apr. 4, 2009 for U.S. Appl. No. 12/203,731, 25 pages.
1.111 Amendment filed Jun. 18, 2010 in U.S. Appl. No. 12/635,228, 14 pages.
Office Action mailed Feb. 28, 2010 in U.S. Appl. No. 12/635,228, 19 pages.

Affiliated with

Also associated with

Rating

RNA interference mediated inhibition of muscarinic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNA interference mediated inhibition of muscarinic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of muscarinic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4293952